Clinical Trial Update: A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and tolerability of DBI-001 in patients with tinea pedis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tinea Pedis

Drugs mentioned

• DBI-001

Snippet

Sponsor: DermBiont, Inc. | Conditions: Tinea Pedis | Phase 2 | Status: COMPLETED | Results posted: 2025-06-17